50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,632.92 (-2.32%)
DOW   29,155.75 (-1.78%)
QQQ   270.58 (-3.34%)
AAPL   143.35 (-4.33%)
MSFT   235.22 (-2.43%)
META   135.85 (-4.07%)
GOOGL   96.37 (-3.68%)
AMZN   113.83 (-3.54%)
TSLA   271.10 (-5.81%)
NVDA   121.23 (-4.81%)
NIO   16.00 (-7.67%)
BABA   77.12 (-4.78%)
AMD   64.63 (-5.46%)
T   15.51 (-2.02%)
MU   49.38 (-3.18%)
CGC   2.80 (-7.89%)
F   11.50 (-5.58%)
GE   62.45 (-3.12%)
DIS   97.24 (-2.17%)
AMC   7.24 (-5.61%)
PYPL   88.90 (-2.44%)
PFE   43.99 (-0.99%)
NFLX   241.08 (-1.68%)
S&P 500   3,632.92 (-2.32%)
DOW   29,155.75 (-1.78%)
QQQ   270.58 (-3.34%)
AAPL   143.35 (-4.33%)
MSFT   235.22 (-2.43%)
META   135.85 (-4.07%)
GOOGL   96.37 (-3.68%)
AMZN   113.83 (-3.54%)
TSLA   271.10 (-5.81%)
NVDA   121.23 (-4.81%)
NIO   16.00 (-7.67%)
BABA   77.12 (-4.78%)
AMD   64.63 (-5.46%)
T   15.51 (-2.02%)
MU   49.38 (-3.18%)
CGC   2.80 (-7.89%)
F   11.50 (-5.58%)
GE   62.45 (-3.12%)
DIS   97.24 (-2.17%)
AMC   7.24 (-5.61%)
PYPL   88.90 (-2.44%)
PFE   43.99 (-0.99%)
NFLX   241.08 (-1.68%)
S&P 500   3,632.92 (-2.32%)
DOW   29,155.75 (-1.78%)
QQQ   270.58 (-3.34%)
AAPL   143.35 (-4.33%)
MSFT   235.22 (-2.43%)
META   135.85 (-4.07%)
GOOGL   96.37 (-3.68%)
AMZN   113.83 (-3.54%)
TSLA   271.10 (-5.81%)
NVDA   121.23 (-4.81%)
NIO   16.00 (-7.67%)
BABA   77.12 (-4.78%)
AMD   64.63 (-5.46%)
T   15.51 (-2.02%)
MU   49.38 (-3.18%)
CGC   2.80 (-7.89%)
F   11.50 (-5.58%)
GE   62.45 (-3.12%)
DIS   97.24 (-2.17%)
AMC   7.24 (-5.61%)
PYPL   88.90 (-2.44%)
PFE   43.99 (-0.99%)
NFLX   241.08 (-1.68%)
S&P 500   3,632.92 (-2.32%)
DOW   29,155.75 (-1.78%)
QQQ   270.58 (-3.34%)
AAPL   143.35 (-4.33%)
MSFT   235.22 (-2.43%)
META   135.85 (-4.07%)
GOOGL   96.37 (-3.68%)
AMZN   113.83 (-3.54%)
TSLA   271.10 (-5.81%)
NVDA   121.23 (-4.81%)
NIO   16.00 (-7.67%)
BABA   77.12 (-4.78%)
AMD   64.63 (-5.46%)
T   15.51 (-2.02%)
MU   49.38 (-3.18%)
CGC   2.80 (-7.89%)
F   11.50 (-5.58%)
GE   62.45 (-3.12%)
DIS   97.24 (-2.17%)
AMC   7.24 (-5.61%)
PYPL   88.90 (-2.44%)
PFE   43.99 (-0.99%)
NFLX   241.08 (-1.68%)
NASDAQ:AQST

Aquestive Therapeutics - AQST Stock Forecast, Price & News

$1.08
-0.08 (-6.90%)
(As of 09/29/2022 10:35 AM ET)
Add
Compare
Today's Range
$1.06
$1.08
50-Day Range
$0.81
$1.73
52-Week Range
$0.62
$6.40
Volume
1,402 shs
Average Volume
1.20 million shs
Market Capitalization
$57.62 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.88

Aquestive Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
736.2% Upside
$9.70 Price Target
Short Interest
Healthy
2.16% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.95mentions of Aquestive Therapeutics in the last 14 days
Based on 9 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.24) to ($0.75) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.94 out of 5 stars

Medical Sector

758th out of 1,096 stocks

Pharmaceutical Preparations Industry

368th out of 548 stocks

AQST stock logo

About Aquestive Therapeutics (NASDAQ:AQST) Stock

Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.

Receive AQST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aquestive Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AQST Stock News Headlines

Why Is Aquestive Therapeutics Stock Up Today?
Where Aquestive Therapeutics Stands With Analysts
Aquestive Therapeutics: A First Take
See More Headlines
Receive AQST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aquestive Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AQST Company Calendar

Last Earnings
8/02/2022
Today
9/29/2022
Next Earnings (Estimated)
11/01/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AQST
Fax
N/A
Employees
157
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$9.70
High Stock Price Forecast
$17.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+629.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-70,540,000.00
Net Margins
-146.34%
Pretax Margin
-146.34%

Debt

Sales & Book Value

Annual Sales
$50.83 million
Book Value
($2.05) per share

Miscellaneous

Free Float
48,149,000
Market Cap
$57.62 million
Optionable
Not Optionable
Beta
3.11

Key Executives

  • Mr. Daniel Barber (Age 46)
    CEO, Pres & Director
    Comp: $750.28k
  • Mr. A. Ernest Toth Jr. (Age 63)
    Sr. VP & CFO
    Comp: $679.9k
  • Mr. Keith J. Kendall (Age 64)
    Consultant
    Comp: $1.03M
  • Mr. Alexander Mark Schobel (Age 63)
    Chief Innovation & Technology Officer
  • Ms. Lori J. Braender BSBA (Age 66)
    Esq., J.D., Sr. VP & Gen. Counsel
  • Ms. Theresa Wood (Age 59)
    Sr. VP of HR
  • Dr. Eric Dadey Ph.D.
    Sr. Vice-Pres of R&D
  • Mr. Peter E. Boyd (Age 56)
    Sr. VP of Bus. Process & Information Technology
  • Mr. Kenneth W. Marshall (Age 63)
    Sr. VP & Chief Commercial Officer
  • Dr. Gary H. Slatko M.D. (Age 65)
    MBA, Sr. VP & Chief Medical Officer













AQST Stock - Frequently Asked Questions

Should I buy or sell Aquestive Therapeutics stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aquestive Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AQST shares.
View AQST analyst ratings
or view top-rated stocks.

What is Aquestive Therapeutics' stock price forecast for 2022?

5 equities research analysts have issued 12-month price objectives for Aquestive Therapeutics' shares. Their AQST share price forecasts range from $5.00 to $17.00. On average, they anticipate the company's stock price to reach $9.70 in the next twelve months. This suggests a possible upside of 736.2% from the stock's current price.
View analysts price targets for AQST
or view top-rated stocks among Wall Street analysts.

How have AQST shares performed in 2022?

Aquestive Therapeutics' stock was trading at $3.89 at the beginning of 2022. Since then, AQST stock has decreased by 70.2% and is now trading at $1.16.
View the best growth stocks for 2022 here
.

When is Aquestive Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our AQST earnings forecast
.

How were Aquestive Therapeutics' earnings last quarter?

Aquestive Therapeutics, Inc. (NASDAQ:AQST) released its earnings results on Tuesday, August, 2nd. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.05. The business had revenue of $13.27 million for the quarter, compared to analysts' expectations of $10.02 million. During the same quarter in the previous year, the firm posted ($0.33) earnings per share.

What guidance has Aquestive Therapeutics issued on next quarter's earnings?

Aquestive Therapeutics issued an update on its FY 2022 earnings guidance on Tuesday, August, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $46.00 million-$49.00 million, compared to the consensus revenue estimate of $46.46 million.

What other stocks do shareholders of Aquestive Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aquestive Therapeutics investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Dynavax Technologies (DVAX), ADMA Biologics (ADMA), Bionano Genomics (BNGO), OrganiGram (OGI), Novan (NOVN), Outlook Therapeutics (OTLK) and KushCo (KSHB).

When did Aquestive Therapeutics IPO?

(AQST) raised $60 million in an initial public offering (IPO) on Wednesday, July 25th 2018. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO and Wedbush PacGrow and JMP Securities were co-managers.

What is Aquestive Therapeutics' stock symbol?

Aquestive Therapeutics trades on the NASDAQ under the ticker symbol "AQST."

How do I buy shares of Aquestive Therapeutics?

Shares of AQST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aquestive Therapeutics' stock price today?

One share of AQST stock can currently be purchased for approximately $1.16.

How much money does Aquestive Therapeutics make?

Aquestive Therapeutics (NASDAQ:AQST) has a market capitalization of $61.89 million and generates $50.83 million in revenue each year. The company earns $-70,540,000.00 in net income (profit) each year or ($1.77) on an earnings per share basis.

How many employees does Aquestive Therapeutics have?

The company employs 157 workers across the globe.

How can I contact Aquestive Therapeutics?

Aquestive Therapeutics' mailing address is 30 TECHNOLOGY DRIVE, WARREN NJ, 07059. The official website for the company is www.aquestive.com. The company can be reached via phone at (908) 941-1900 or via email at investorrelations@aquestive.com.

This page (NASDAQ:AQST) was last updated on 9/29/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.